ArticleClinical neuropathology
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Article in Clinical neuropathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.Journal of translational medicine · 2023Article
- Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma.Disease markers · 2022Article
- Identification of key modules and hub genes in glioblastoma multiforme based on co-expression network analysis.FEBS open bio · 2021Article
- The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting PrognosisBalkan medical journal · 2019Article
- Article
- Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach.Journal of pathology and translational medicine · 2018Article
- ATRX immunostaining predicts IDH and H3F3A status in gliomas.Acta neuropathologica communications · 2016Article
- Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.Pathology oncology research : POR · 2016Article
- Heavy metals and epigenetic alterations in brain tumors.Current genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome-wide molecular approaches have substantially elucidated molecular alterations and pathways involved in the oncogenesis of brain tumors. In gliomas, several molecular biomarkers including IDH mutation, 1p/19q co-deletion, and MGMT promotor methylation status have been introduced into neuropathological practice. Recently, mutations of the ATRX gene have been found in various subtypes and grades of gliomas and were shown to refine the prognosis of malignant gliomas in combination with IDH and 1p/19q status. Mutations of ATRX are associated with loss of nuclear ATRX protein expression, detectable by a commercially available antibody, thus turning ATRX into a promising prognostic candidate biomarker in the routine neuropathological setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.